Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Observer-blind, Randomized, Active Controlled Trial to Assess the Safety of an Investigational Meningococcal Serogroups ACYWX Conjugate Vaccine (NmCV-5) and Compare Its Immunogenicity to a Licensed Meningococcal Serogroups ACYW Conjugate Vaccine (Menactra®), in Healthy Subjects 2 to 29 Years of Age

NCT03964012 is registered in ClinicalTrials.gov with Serum Institute of India Pvt. Ltd. as lead sponsor.

NCT NCT03964012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03964012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Observer-blind, Randomized, Active Controlled Trial to Assess the Safety of an Investigational Meningococcal Serogroups ACYWX Conjugate Vaccine (NmCV-5) and Compare Its Immunogenicity to a Licensed Meningococcal Serogroups ACYW Conjugate Vaccine (Menactra®), in Healthy Subjects 2 to 29 Years of Age
Lead sponsor
Serum Institute of India Pvt. Ltd.
Phase
Phase 3
Overall status
Completed
Start date
August 20, 2019
Completion date
March 4, 2021
Enrollment
1,800 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal meningitis